Feto-maternal care
Conditions
Interventions
185mg ferrous Fumarate and 400mcg folic acid
Sponsors
self
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: i. Women between gestational ages of 13 to 20 weeks that consent for the study. ii. Women of reproductive age group (15 to 49 years). iii Women who are willing to deliver in our facility.
Exclusion criteria
Exclusion criteria: I. Pregnant women with anaemia in pregnancy II. Pregnant women with G.A <13weeks and above 20weeks G.A. III. Patients that have commenced the use of any of the tested supplements at any time before presentation to the booking clinic in the index pregnancy. IV. Patients with severe, acute or chronic, hepatic or renal failure, cardiac insufficiency. V. Sickle cell disease patients VI. Patients with multiple gestation VII. Non-consenting women VIII. Patient with previous preeclampsia IX. Patient with previous preterm delivery X. Patient with previous postpartum hemorrhage secondary to uterine atony
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anemia in the mother and birth weight at delivery in the baby. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Duration of pregnancy 2 Maternal weight gain at 28weeks and at delivery 3. Neonatal birth weight, length and head circumference, APGAR scores 4. Need for NICU admission 5. Haemoglobin level of pregnant women at 28 weeks and at delivery 6. Detection of pre eclampsia 7. Estimated blood loss at delivery 8. Compliance with supplements 9. Side effects of supplements: 10. Maternal and neonatal outcome such as: 10.1. Abruptio placenta 10.2. Type of delivery 10.3. Miscarriage /still born/neonatal death in the first 24 hours 11. Delivery complications such as: 11.1. Postpartum hemorrhage 11.2. Need for blood transfusion | — |
Countries
Nigeria
Contacts
Public ContactHabib Ibrahim
consultant
Outcome results
None listed